IN2014DN09351A - - Google Patents
Info
- Publication number
- IN2014DN09351A IN2014DN09351A IN9351DEN2014A IN2014DN09351A IN 2014DN09351 A IN2014DN09351 A IN 2014DN09351A IN 9351DEN2014 A IN9351DEN2014 A IN 9351DEN2014A IN 2014DN09351 A IN2014DN09351 A IN 2014DN09351A
- Authority
- IN
- India
- Prior art keywords
- filovirus
- ebolavirus
- consensus
- marburgvirus
- immunogen
- Prior art date
Links
- 241001115376 Sudan ebolavirus Species 0.000 abstract 5
- 241001115402 Ebolavirus Species 0.000 abstract 4
- 241001115401 Marburgvirus Species 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 4
- 102000003886 Glycoproteins Human genes 0.000 abstract 3
- 108090000288 Glycoproteins Proteins 0.000 abstract 3
- 241000711950 Filoviridae Species 0.000 abstract 2
- 208000007136 Filoviridae Infections Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 241001115400 Zaire ebolavirus Species 0.000 abstract 1
- 108700010787 filovirus proteins Proteins 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623428P | 2012-04-12 | 2012-04-12 | |
| PCT/US2013/036413 WO2013155441A1 (en) | 2012-04-12 | 2013-04-12 | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09351A true IN2014DN09351A (uk) | 2015-07-17 |
Family
ID=49328209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9351DEN2014 IN2014DN09351A (uk) | 2012-04-12 | 2013-04-12 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9597388B2 (uk) |
| EP (2) | EP4190350A1 (uk) |
| JP (4) | JP6389163B2 (uk) |
| KR (4) | KR102146904B1 (uk) |
| CN (2) | CN110051835A (uk) |
| AU (1) | AU2013245729B2 (uk) |
| CA (2) | CA3194125A1 (uk) |
| IN (1) | IN2014DN09351A (uk) |
| WO (1) | WO2013155441A1 (uk) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102146904B1 (ko) | 2012-04-12 | 2020-08-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| WO2015127140A2 (en) * | 2014-02-19 | 2015-08-27 | Jody Berry | Marburg monoclonal antibodies |
| EP2944321A1 (en) * | 2014-05-12 | 2015-11-18 | Institut De Recherche Pour Le Développement (IRD) | Immunogenic peptides of EBOLA and applications thereof |
| KR20190062617A (ko) * | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| CN112972668A (zh) * | 2014-09-03 | 2021-06-18 | 巴法里安诺迪克有限公司 | 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗 |
| HRP20240163T1 (hr) * | 2014-09-03 | 2024-04-12 | Bavarian Nordic A/S | Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom |
| KR20230145241A (ko) * | 2014-10-01 | 2023-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신 |
| WO2016079572A1 (en) * | 2014-11-21 | 2016-05-26 | Wayengara Misaki | Conserved b cell epitopes of filovirus glycoprotein and their use as either biomarkers or therapeutics and sub-unit vaccines for ebola virus and marburg virus |
| US20170326225A1 (en) * | 2014-12-16 | 2017-11-16 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| CA2974114A1 (en) * | 2015-01-28 | 2016-08-04 | Integrated Biotherapeutics, Inc. | Equine immunoglobulin compositions and uses for treating filovirus-mediated diseases |
| CN105582532A (zh) * | 2015-08-30 | 2016-05-18 | 李小彦 | 可溶性埃博拉病毒包膜蛋白疫苗的制备方法及其用途 |
| CN110072536B (zh) * | 2016-05-05 | 2024-02-02 | 宾夕法尼亚大学理事会 | 丝状病毒共有抗原、核酸构建体和由其制成的疫苗及其使用方法 |
| WO2017211843A1 (en) * | 2016-06-07 | 2017-12-14 | Abivax | Antiviral polyclonal antibodies against ebola virus and the uses thereof |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US11186626B2 (en) * | 2016-10-11 | 2021-11-30 | Integrated Biotherapeutics, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
| EA201892124A1 (ru) * | 2016-12-02 | 2019-04-30 | Дэвид Б. Уэйнер | Днк-конструкции антител и способы их применения |
| US11129886B2 (en) * | 2017-03-28 | 2021-09-28 | Children's Hospital Medical Center | VLP-based bivalent Ebola vaccines and methods of making and using same |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| NL268156A (uk) | 1960-08-22 | |||
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| DE69434469T2 (de) | 1993-01-26 | 2006-06-14 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| US6200959B1 (en) * | 1996-12-04 | 2001-03-13 | Powerject Vaccines Inc. | Genetic induction of anti-viral immune response and genetic vaccine for filovirus |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US6110161A (en) | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| DE69826124T3 (de) | 1997-06-30 | 2007-10-11 | Institut Gustave Roussy | Verabreichung der nukleinsäure in den quergestreiften muskel |
| WO1999064615A1 (en) | 1998-06-08 | 1999-12-16 | Valentis, Inc. | Formulations for electroporation |
| EP1100579B1 (en) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| WO2002079239A2 (en) * | 2001-01-31 | 2002-10-10 | U.S. Army Medical Research Institute Of Infectious Diseases | Chimeric filovirus glycoprotein |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| DE60226911D1 (de) * | 2001-10-01 | 2008-07-10 | Us Health | Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten |
| US7211378B2 (en) | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| WO2003092582A2 (en) * | 2002-04-30 | 2003-11-13 | The Trustees Of The University Of Pennsylvania | Chimeric ebola virus envelopes and uses therefor |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US20040175727A1 (en) | 2002-11-04 | 2004-09-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| WO2004108260A2 (en) | 2003-05-30 | 2004-12-16 | Advisys, Inc. | Devices and methods for biomaterial production |
| NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| JP5046941B2 (ja) * | 2004-09-27 | 2012-10-10 | アメリカ合衆国 | エボラ及び他のウイルスに対する防御に最適化されたワクチン |
| NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| WO2009116982A2 (en) | 2007-12-18 | 2009-09-24 | Trustees Of Boston University | Pre-or post-exposure treatment for filovirus or arenavirus infection |
| CA2720168C (en) * | 2008-04-04 | 2024-04-30 | David B. Weiner | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
| EP2303312B1 (en) * | 2008-05-28 | 2016-03-30 | Inovio Pharmaceuticals, Inc. | Smallpox dna vaccine and the antigens therein that elicit an immune response |
| BRPI0921359A2 (pt) * | 2008-11-17 | 2015-08-25 | Inovio Pharmaceuticals Inc | Antígenos que induzem a resposta imunológica contra flavivírus e métodos de uso dos mesmos |
| CN106318978B (zh) | 2008-11-21 | 2020-06-23 | 巴法里安诺迪克有限公司 | 包含多个同源核苷酸序列的载体 |
| US9097713B2 (en) * | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| US8956865B2 (en) | 2010-08-11 | 2015-02-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of growing an embryo to a blastocyst stage of development |
| EP2632484B1 (en) * | 2010-10-28 | 2018-02-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Filovirus fusion proteins and their uses |
| EP2670843B1 (en) * | 2011-02-03 | 2014-10-29 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Multivalent vaccines for rabies virus and filoviruses |
| KR102146904B1 (ko) * | 2012-04-12 | 2020-08-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
| TWI548337B (zh) | 2015-10-16 | 2016-09-01 | 技嘉科技股份有限公司 | 散熱模組、顯示卡組件及電子裝置 |
-
2013
- 2013-04-12 KR KR1020147031462A patent/KR102146904B1/ko active IP Right Grant
- 2013-04-12 IN IN9351DEN2014 patent/IN2014DN09351A/en unknown
- 2013-04-12 AU AU2013245729A patent/AU2013245729B2/en active Active
- 2013-04-12 EP EP22194245.1A patent/EP4190350A1/en active Pending
- 2013-04-12 KR KR1020247001336A patent/KR20240010758A/ko active Application Filing
- 2013-04-12 KR KR1020227001066A patent/KR20220012403A/ko not_active IP Right Cessation
- 2013-04-12 KR KR1020207023636A patent/KR102351881B1/ko active IP Right Grant
- 2013-04-12 US US14/391,952 patent/US9597388B2/en active Active
- 2013-04-12 JP JP2015505951A patent/JP6389163B2/ja active Active
- 2013-04-12 CA CA3194125A patent/CA3194125A1/en active Pending
- 2013-04-12 EP EP13775813.2A patent/EP2836230B1/en active Active
- 2013-04-12 WO PCT/US2013/036413 patent/WO2013155441A1/en active Application Filing
- 2013-04-12 CN CN201910150339.2A patent/CN110051835A/zh active Pending
- 2013-04-12 CN CN201380030601.0A patent/CN104884083A/zh active Pending
- 2013-04-12 CA CA2870293A patent/CA2870293C/en active Active
-
2017
- 2017-02-13 US US15/431,203 patent/US10034930B2/en active Active
-
2018
- 2018-07-31 US US16/050,142 patent/US10765733B2/en active Active
- 2018-08-16 JP JP2018153310A patent/JP7164353B2/ja active Active
-
2020
- 2020-08-27 US US17/004,818 patent/US11723969B2/en active Active
- 2020-09-14 JP JP2020153758A patent/JP2021001191A/ja active Pending
-
2022
- 2022-03-14 JP JP2022039450A patent/JP2022078289A/ja active Pending
-
2023
- 2023-07-05 US US18/347,120 patent/US20240100143A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09351A (uk) | ||
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| MX359954B (es) | Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado. | |
| MX2016016722A (es) | Coronavirus. | |
| PH12017500614A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| MX361728B (es) | Ácido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilación para incrementar la expresión de un antígeno tumoral codificado. | |
| BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
| MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
| NZ729012A (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| UA116915C2 (uk) | Вектор, що кодує антигенний пептид, та спосіб підвищення стійкості до інфекцій, що викликаються campylobacter | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| EP4324845A3 (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
| MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| AU2013358947A8 (en) | WT1 vaccine | |
| MX2016012551A (es) | Gen modificado que confiere resistencia a virus. | |
| CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
| MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
| GEP20197052B (en) | Hyr1-derived compositions and methods of treatment using same | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| WO2013006050A9 (en) | Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) |